[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7462
1. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


2. Perez VA, Swigris J, Ruoss SJ: Coexistence of primary adenocarcinoma of the lung and Tsukamurella infection: a case report and review of the literature. J Med Case Rep; 2008;2:207
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of primary adenocarcinoma of the lung and Tsukamurella infection: a case report and review of the literature.
  • INTRODUCTION: A major diagnostic challenge in the evaluation of a cavitary lung lesion is to distinguish between infectious and malignant etiologies.
  • However, despite clinical improvement with antibiotic therapy targeted to the organism, concomitant discovery of a papillary thyroid carcinoma led to a needle biopsy of the cavitary lesion, which showed evidence of primary lung adenocarcinoma.
  • CONCLUSION: This is the first description of Tsukamurella infection in the setting of primary lung carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 1999 Aug;92(8):831-2 [10456728.001]
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):e72-7 [12228839.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3368-71 [12843095.001]
  • [Cites] Pathol Biol (Paris). 1997 Jan;45(1):60-5 [9097849.001]
  • [Cites] J Clin Microbiol. 1982 Oct;16(4):604-7 [7153308.001]
  • [Cites] Int J Syst Bacteriol. 1996 Apr;46(2):429-36 [8934902.001]
  • [Cites] J Infect. 2004 Jul;49(1):17-9 [15194243.001]
  • (PMID = 18554413.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2442117
  •  go-up   go-down


3. Zakowski MF, Hussain S, Pao W, Ladanyi M, Ginsberg MS, Heelan R, Miller VA, Rusch VW, Kris MG: Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med; 2009 Mar;133(3):470-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
  • CONTEXT: A subset of lung adenocarcinomas appears preferentially sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
  • OBJECTIVES: To describe the morphology of adenocarcinomas responsive to TKIs, compare it to tumors in nonresponding patients, and correlate findings with EGFR mutations, gene copy number, and protein expression.
  • Adenocarcinoma subtypes and morphologic features were defined in histologic and cytologic material.
  • RESULTS: Tumors from TKI responders tended to be better-differentiated adenocarcinomas with bronchioloalveolar carcinoma components.
  • Using World Health Organization criteria, all tumors in both groups other than pure bronchioloalveolar carcinomas would be classified as adenocarcinomas, mixed subtype, thereby obscuring some of these distinctions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):29-34 [11241263.001]
  • [Cites] Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7 [12440623.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2658-63 [12860941.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Semin Cancer Biol. 2004 Feb;14(1):33-40 [14757534.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4227s-4232s [15217963.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):208-12 [15187994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):887-94 [2996275.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Diagn Cytopathol. 1997 Mar;16(3):253-7 [9099548.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):109-15 [15386420.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7311-7 [15534107.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):118-22 [15725915.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):633-9 [15832087.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] J Med Assoc Thai. 2005 Sep;88 Suppl 4:S322-9 [16623049.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1309-15 [17001163.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):581-7 [17186532.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):741-50 [17238183.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):320-6 [17591931.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • (PMID = 19260752.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121210
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS578987; NLM/ PMC4016915
  •  go-up   go-down


Advertisement
4. Barlési F, Pinot D, Legoffic A, Doddoli C, Chetaille B, Torre JP, Astoul P: Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer; 2005 Aug 22;93(4):450-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung.
  • This study investigated the relation between positive thyroid transcription factor 1 (TTF1) staining and survival of patients affected by primary adenocarcinoma (ADC) of the lung.
  • In conclusion, positive TTF1 staining strongly and independently correlates with survival of patients with primary ADC of the lung.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Lung Neoplasms / chemistry. Nuclear Proteins / analysis. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2004 Apr;57(4):383-7 [15047742.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):318-24 [10102618.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):363-72 [11224607.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):767-73 [12023581.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):3-7 [14745718.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S35-49 [12915902.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):494-500 [12923324.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):103-9 [12051626.001]
  • (PMID = 16052216.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  • [Other-IDs] NLM/ PMC2361585
  •  go-up   go-down


5. Glynn C, Zakowski MF, Ginsberg MS: Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol; 2010 Mar;5(3):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
  • PURPOSE: To identify any particular imaging features on computed tomography (CT) in patients with confirmed adenocarcinoma with bronchioloalveolar (ABAC) features and known epidermal growth factor receptor (EGFR) and KRAS mutations.
  • Seventy-seven pulmonary nodules in 64 patients with a histologic diagnosis of ABAC and known EGFR or KRAS mutation status were assessed.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Lung Neoplasms / genetics. Lung Neoplasms / radiography. Mutation / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087229.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Casali C, Rossi G, Marchioni A, Sartori G, Maselli F, Longo L, Tallarico E, Morandi U: A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol; 2010 Jun;5(6):830-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice.
  • METHODS: Retrospective analysis of resected BAC reclassified according to the 2004 World Health Organization classification of lung tumors.
  • Locally advanced nonmucinous BAC has a poor prognosis: the diagnosis of nonmucinous BAC in large tumors should be interpreted with caution given the possible presence of invasive areas in incompletely sampled tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20521350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


7. Vignoli M, Rossi F, Chierici C, Terragni R, De Lorenzi D, Stanga M, Olivero D: Needle tract implantation after fine needle aspiration biopsy (FNAB) of transitional cell carcinoma of the urinary bladder and adenocarcinoma of the lung. Schweiz Arch Tierheilkd; 2007 Jul;149(7):314-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle tract implantation after fine needle aspiration biopsy (FNAB) of transitional cell carcinoma of the urinary bladder and adenocarcinoma of the lung.
  • Primary tumors were two transitional cell carcinomas of the urinary bladder (2 dogs) and one pulmonary adenocarcinoma (1 cat).
  • To our knowledge, the seeding of pulmonary adenocarcinoma cells after FNAB on the thoracic wall has never been reported in veterinary medicine.
  • [MeSH-major] Adenocarcinoma / veterinary. Carcinoma, Transitional Cell / veterinary. Cat Diseases / pathology. Dog Diseases / pathology. Lung Neoplasms / veterinary. Neoplasm Seeding. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Abdominal Wall / pathology. Animals. Biopsy, Fine-Needle / adverse effects. Biopsy, Fine-Needle / veterinary. Cats. Diagnosis, Differential. Dogs. Fatal Outcome. Female. Male

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702491.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Summers RJ, Shehata BM, Bleacher JC, Stockwell C, Rapkin L: Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. J Pediatr Surg; 2010 Nov;45(11):2256-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation.
  • Congenital pulmonary airway malformation (CPAM) is a rare developmental abnormality of the lung that has been associated with the presence of rhabdomyosarcoma, pleuropulmonary blastoma, and most commonly bronchioalveolar carcinoma (BAC) of the lung.
  • Here, we report the case of an 8-year-old patient who developed KRAS mutation positive stage IV mucinous adenocarcinoma of the lung in association with CPAM.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cystic Adenomatoid Malformation of Lung, Congenital / diagnosis. Lung Neoplasms / diagnosis. Precancerous Conditions
  • [MeSH-minor] Bronchoscopy. Child. Diagnosis, Differential. Female. Humans. Pneumonectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21034957.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Gerosa M, Nicolato A, Foroni R, Tomazzoli L, Bricolo A: Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg; 2005 Jan;102(s_supplement):75-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery.
  • OBJECT: The authors conducted a study to evaluate the long-term outcomes and prognostic factors for survival in a large series of patients treated by gamma knife surgery (GKS) for non-small cell lung cancer (NSCLC) brain metastases.
  • The most common histological types were adenocarcinoma (51%) and squamous cell carcinoma (27%).
  • Analysis of long-term outcomes seemed to confirm that GKS is a primary therapeutic option in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306429.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / non—small cell lung cancer
  •  go-up   go-down


10. Kato T, Nakashima M, Yoshimura K, Imao M, Goto H, Yasuda S, Sano K: [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2005 Nov;43(11):700-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
  • BACKGROUND: Tumor response rate to gefitinib by previously treated patients with advanced non-small-cell lung cancer was approximately 20%.
  • CASE: A 40-year-old man was given a diagnosis of adenocarcinoma of lung (c-T2N3M1).
  • Reduction of the primary tumor, brain metastasis, pulmonary metastasis and liver metastasis was seen.
  • Recurrence of pulmonary metastasis and liver metastasis was discovered 8 months after treatment with gefitinib.
  • However, primary tumor, pulmonary metastasis and liver metastasis progressed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Lung Neoplasms / pathology. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


11. Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, Gemba K, Aoe K, Shibayama T, Matsuo K, Kamei H, Fujiwara Y, Bessho A, Moritaka T, Sugimoto K, Tabata M, Ueoka H, Tanimoto M: Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol; 2009 Jan;135(1):117-23
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
  • BACKGROUND: Gefitinib is effective in patients with lung adenocarcinoma.
  • Smoking status also affects the responsiveness to gefitinib, but it has not been fully evaluated whether a sex difference exists in the influence of smoking on the efficacy of gefitinib in patients with lung adenocarcinoma.
  • METHODS: We reviewed the clinical records of 260 Japanese patients with lung adenocarcinoma who received gefitinib therapy (250 mg/day), and whose smoking status was known.
  • CONCLUSIONS: In male patients with lung adenocarcinoma, cumulative smoking significantly affected response and survival following gefitinib treatment, while in female patients, responsiveness to gefitinib was independent of smoking status.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Smoking / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1580-6 [9362155.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3227-34 [15886310.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):896-903 [16552419.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):96-101 [17054433.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2032-8 [10580029.001]
  • [Cites] Jpn J Clin Oncol. 2001 Dec;31(12):596-600 [11902490.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1782-9 [15550583.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):632-7 [17607119.001]
  • [Cites] Curr Opin Oncol. 2006 Mar;18(2):135-43 [16462182.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):1-5 [14698531.001]
  • [Cites] Lung Cancer. 2008 Nov;62(2):236-41 [18485523.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):357-64 [8707409.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):229-39 [12619108.001]
  • [Cites] J Thorac Oncol. 2007 Jan;2(1):96 [17410021.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Med Clin North Am. 1992 Mar;76(2):289-303 [1548962.001]
  • [Cites] J Natl Cancer Inst. 1994 Jun 1;86(11):869-70 [8182770.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Carcinogenesis. 1996 Oct;17(10):2201-5 [8895489.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Acta Oncol. 2005;44(7):717-22 [16227162.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Lung Cancer. 2004 Nov;46(2):255-61 [15474674.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3852-9 [15326195.001]
  • (PMID = 18618142.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


12. Park EA, Lee HJ, Kim YT, Kang CH, Kang KW, Jeon YK, Goo JM, Lee CH, Park CM: EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. Lung Cancer; 2009 May;64(2):179-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology.
  • However, imaging features related to EGFR gene copy number status in adenocarcinoma are still unknown.
  • We therefore retrospectively analyzed CT, FDG-PET, and histopathologic slides of surgical resected lung adenocarcinoma in 132 patients.
  • A high proportion of GGO, small tumor diameter on CT, and a well-differentiated histopathology were more frequent in FISH-negative adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Lung Neoplasms / genetics. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819724.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Computed tomography of the chest revealed diffuse ground glass opacities in both lungs, and magnetic resonance imaging of the brain showed multiple acute infarctions.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


15. Sohn MH, Kim MW, Lim ST, Lee NR, Song EK, Yim CY: Radioiodine uptake by metastatic nonthyroidal adenocarcinoma of the lung in a patient with papillary thyroid carcinoma. Clin Nucl Med; 2005 Apr;30(4):269-70
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioiodine uptake by metastatic nonthyroidal adenocarcinoma of the lung in a patient with papillary thyroid carcinoma.
  • A 49-year-old woman with a history of a hysterectomy for carcinoma of the cervix and papillary thyroid carcinoma showed multiple pulmonary metastases on chest radiography.
  • These lesions were found to be metastatic cervical adenocarcinoma.
  • The radioiodine uptake by the metastatic cervical adenocarcinoma of the lungs occurred in the presence of normal thyroid imaging in a patient with a thyroid nodule and papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / radionuclide imaging. Iodine Radioisotopes / pharmacokinetics. Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / radionuclide imaging. Diagnosis, Differential. Female. Humans. Middle Aged. Radiopharmaceuticals / pharmacokinetics. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764888.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals
  •  go-up   go-down


16. Han J, Lee S, Yun T, Moon Y, Park I, Kim H, Lee J: Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of gefitinib alone or with simvastatin in previously treated advanced non-small cell lung cancer (NSCLC).
  • Dolichol has a stimulatory effect on DNA synthesis and is linked to several tumor cell proteins.
  • GPP and FPP cause isoprenylation of Ras and Rho those regulate signal transduction of several membrane receptors crucial for cell proliferation, differentiation, and apoptosis, which result in resistance to gefitinib.
  • METHODS: Between May 2006 and September 2008, 107 patients (51% male, 74% adenocarcinoma, 50% never-smoker, 54% more than two prior regimens) were randomly assigned to gefitinib alone (250 mg/d orally, n=53) or gefitinib plus simvastatin (250mg/d and 40 mg/d orally, respectively, n=54).
  • In subgroup analysis, gefitinib plus simvastatin showed a trend for higher RR than gefitinib alone in non-adenocarcinoma group (38.5% vs. 7.7%, p=0.08).
  • CONCLUSIONS: Gefitinib combined with simvastatin did not improved efficacy compared to gefitinib alone in this unselected patient population, but showed a trend for higher efficacy in non-adenocarcinoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sorensen J, Hansen O, Vilmar A, Frank H: Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized phase III trial of triplet chemotherapy with paclitaxel + gemcitabine + cisplatin compared to standard doublet chemotherapy with vinorelbine + cisplatin in advanced non-small cell lung cancer.
  • Overall, median age was 62 years (range 38-75 yrs), 58% were males, 11% had performance status 2, 62% stage IV disease, 46% adenocarcinoma, and 28% squamous cell carcinoma (SCC), equally distributed between the regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962834.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sugarbaker DJ, Tilleman TR, Swanson SJ, Jaklitsch MT, Mentzer SJ, Mujoomdar AA, Bueno R: The role of extrapleural pneumonectomy in the management of pleural cancers. J Clin Oncol; 2009 May 20;27(15_suppl):7577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7577 Background: We report our experience with EPP for non-mesothelial malignancies.
  • Of these, 32 patients had mediastinoscopy negative T4 lung cancer, 11 had metastases to only one pleura from extrathoracic sites, 10 had unilateral lung sarcomas involving the pleural envelope, 8 had thymomas metastatic to a pleural space, 2 were preoperatively diagnosed as mesotheliomas but at final pathology were determined to be small cell lung cancer and sarcomatoid carcinoma, and 2 represented primary mucoepidermoid and neuroectodermal malignancies.
  • Twenty-eight patients had stage IIIB (T4-N0-1) lung adenocarcinoma representing the largest homogeneous group of patients by cell type and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lind JS, Dingemans AC, Groen HJ, Smit EF: A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC).
  • In addition circulating endothelial cell (CEC) numbers, plasma VEGF, tumor metabolic activity (<sup>18</sup>FDG-PET), and tumor blood flow (H<sub>2</sub><sup>15</sup>O-PET) were measured.
  • The primary endpoint was the rate of non-progression (NPR) at 6 weeks.
  • RESULTS: 50 pts were enrolled: 22 females; median age 60 yrs (range 41-78); 30 PS 0; 37 stage IV; 34 adenocarcinoma; 11 never smokers; 10/33 EGFR mutations (exons 19 (n=5), 20 (n=1), 21 (n=4)); 3/33 K-Ras mutations.
  • The NPR at 6 weeks was 76%: 13 PR, 25 SD, 8 PD, 4 NE.
  • <sup>18</sup>FDG SUV decreased more in clinical (RECIST) responders than non-responders (-51% vs -18.5%, p=0.031).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Shih J, Yang C, Su W, Hsia T, Tsai C, Chen Y, Chang H, Terlizzi E, Shahidi M, Miller VA: A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2). J Clin Oncol; 2009 May 20;27(15_suppl):8013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2).
  • A phase II trial evaluating the efficacy of BIBW 2992 (Tovok), a novel, potent, irreversible, dual EGFR and HER2 TKI with preclinical activity in cell lines harboring activating (H3255, IC<sub>50</sub>=0.7 nM) and resistant (H1975, IC<sub>50</sub>=99 nM) EGFR mutations, is reported.
  • Eligible pts have stage IIIB/IV lung adenocarcinoma, EGFR mutation in exons 18-21 (tested by direct sequencing), measurable disease, ECOG PS 0-2 and adequate end organ function.
  • An international Phase III trial program investigating BIBW 2992 in NSCLC, LUX-Lung, is now recruiting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962806.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Shao Y, Lin Z, Hu F, Yu C, Shih J, Hu W, Chang Y, Cheng A, Yang P, Yang C: Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):9614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in advanced non-small cell lung cancer patients receiving first-line gefitinib monotherapy.
  • : 9614 Background: Gefitinib is a potential first-line treatment option for patients with advanced non-small cell lung cancer (NSCLC), especially for patients with activating mutations in the EGFR gene.
  • HRQOL was assessed monthly with the EuroQoL instrument (EQ-5D) and the Lung Cancer Symptom Scale (LCSS) questionnaire.
  • Baseline EQ-5D index (estimated hazard ratio = 0.286, 95% C.I.: 0.135-0.603, p = 0.001) and the presence of L858R EGFR mutation in adenocarcinoma (estimated hazard ratio = 0.520, 95% C.I.: 0.307-0.880, p = 0.015) were retained as independent prognostic factors in the final multiple Cox's proportional hazards model for TTF.
  • CONCLUSIONS: In advanced NSCLC patients receiving first-line gefitinib, better baseline EQ-5D index and L858R EGFR mutation in adenocarcinoma predict longer TTF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sugio K, Nagashima A, Nakanishi R, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Takenoyama M, Hanagiri T, Yasumoto K: Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of the biweekly schedule of adjuvant chemotherapy with carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with non-small cell lung cancer (NSCLC).
  • The patients were stratified by gender, histology (adenoca vs. non-adenoca) and disease stage.
  • The histologic types included adenocarcinoma (n=51), squamous cell carcinoma (n=18), large cell carcinoma (n=5), and adenosquamous cell carcinoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N: Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project. J Clin Oncol; 2009 May 20;27(15_suppl):1540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-size relationship in long-term repeated CT screening for lung cancer: Anti-Lung Cancer Association project.
  • : 1540 Background: We have investigated the individualized benefit of CT screening as Anti-Lung Cancer Association projects (presented at ASCO 2006-2008).
  • However, there has not been enough information about the relationship of lung cancer stage to tumor size in repeated CT screening.
  • Therefore, we evaluated the stage-size relationship of these asymptomatic lung cancer cases diagnosed by long-term repeated screening with low-dose helical CT.
  • Histology for the categories 15 mm or less was localized bronchioloalveolar carcinoma in 13 cases, adenocarcinoma with mixed subtype in 11 cases, invasive adenocarcinoma in five cases, other non-small cell carcinoma in 10 cases, and small cell carcinoma in one case.
  • CONCLUSIONS: These results provide direct evidence of a stage-size relationship in long-term repeated CT screening for lung cancer.
  • Furthermore, early detection of lung cancer of 15 mm or less in diameter leads to the detection of early-stage (N0M0) lung cancer in repeated CT screening.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer; 2010 Sep 1;11(5):E1-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
  • Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC).
  • Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of metastatic SCLC carrying an EGFR mutation.
  • Epidermal growth factor receptor mutation analysis revealed that the exon 21 L858R activating mutation was present in both the original lung adenocarcinoma and the metastatic SCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Aged. Female. Humans. Liver Neoplasms / secondary. Mutation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20837450.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


25. Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S, Moriuchi T: Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer; 2007 Dec;58(3):376-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
  • In this study, using quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR), we have analysed RECK expression levels in resected non-small-cell lung cancer (NSCLC) tissue and compared these data with the clinicopathological features of these patients to investigate the role of RECK in NSCLC.
  • Tissue samples of primary lung cancers were obtained from a total of 83 patients [46 with adenocarcinomas (ADC) and 37 with squamous cell carcinomas (SCC)] who underwent curative resection.
  • The samples were taken from 83 tumours and 20 matched normal lung tissue samples as controls.
  • In conclusion, our study suggests that suppression of RECK expression is involved in the progression of ADC of the lung and that RECK expression in resected ADC of the lung is a favorable predictor of patients' prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor. Gene Expression Regulation, Neoplastic. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Membrane Glycoproteins / metabolism
  • [MeSH-minor] Aged. Disease-Free Survival. Female. GPI-Linked Proteins. Humans. Male. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasms, Squamous Cell / genetics. Neoplasms, Squamous Cell / metabolism. Neoplasms, Squamous Cell / pathology. Neoplasms, Squamous Cell / surgery. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714826.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RECK protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


26. Segawa M, Seki K, Kusajima Y, Saito K: [Primary clear cell adenocarcinoma of the lung with endobronchial polypoid growth: report of a case]. Kyobu Geka; 2009 Dec;62(13):1182-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary clear cell adenocarcinoma of the lung with endobronchial polypoid growth: report of a case].
  • Clear cell adenocarcinoma with endobronchial polypoid growth of the lung is extremely rare.
  • A 65-year-old male with hemosputum was found to have an abnormal shadow in the hilum of the left lung.
  • Computed tomography of the chest revealed that a heterogeneous mass occupied the lumen extending outside the upper lobe bronchus of the left lung.
  • By biopsy, the tumor was determined to be adenocarcinoma.
  • Microscopically, most of the tumor was composed of large clear cells with partial glandular formation, indicating the tumor to be adenocarcinoma Lymph node metastasis was seen in #5 and #12u.
  • The lung cancer was diagnosed as clear cell adenocarcinoma with endobronchial polypoid growth.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Bronchi / pathology. Lung Neoplasms / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999100.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, Sung SW, Kim JH: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer; 2008 Jan;59(1):111-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
  • Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhibitors is associated with somatic changes of EGFR in the advanced stage of lung cancer.
  • However, there is no clear data demonstrating whether such molecular changes of EGFR per se can affect the clinical outcome of early stage cancer after surgical resection.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • EGFR mutation was more frequently found in cases with BAC features (13/22 (59.1%):13/49 (26.5%); p=0.008) and in non-smokers (19/41 (46.3%):7/30 (23.3%); p=0.047).
  • The presence of EGFR mutation was not a prognostic factor of the clinical outcome of early lung cancer after surgical resection.
  • This result provides an important message for the protocol design of future trials of EGFR inhibitors in early lung cancer.
  • DNA mutations of EGFR and KRAS were investigated in 71 adenocarcinoma patients who received surgical resection.
  • Whereas KRAS mutation was a poor prognostic factor, EGFR mutation was not, and its presence per se did not affect the clinical outcome of early lung cancer after surgical resection.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904685.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


28. Choi CM, Seo KW, Jang SJ, Oh YM, Shim TS, Kim WS, Lee DS, Lee SD: Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients. Lung Cancer; 2009 Apr;64(1):66-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability is a risk factor for poor prognosis of adenocarcinoma of the lung: Fluorescence in situ hybridization analysis of paraffin-embedded tissue from Korean patients.
  • BACKGROUND: In this study, we sought to evaluate the prognostic importance of chromosomal instability (CIN) in adenocarcinoma (AC) of the lung.
  • METHODS: Sixty-three surgical specimens of lung AC were analyzed.
  • CONCLUSIONS: CIN can be effectively detected in primary AC of lung using FISH analysis.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomal Instability. Chromosomes, Human, Pair 6 / genetics. Lung Neoplasms / genetics. Neoplasm Proteins / genetics. Proto-Oncogene Proteins c-myc / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814932.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Proto-Oncogene Proteins c-myc; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


29. Kozuki T, Hisamoto A, Tabata M, Takigawa N, Kiura K, Segawa Y, Nakata M, Mandai K, Eguchi K, Ueoka H, Tanimoto M: Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer; 2007 Oct;58(1):30-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
  • Recently, a mutation of the epidermal growth factor receptor (EGFR) gene has been reported to be implicated in the development of pulmonary adenocarcinoma.
  • However, the involvement of the mutation in atypical adenomatous hyperplasia (AAH) and multiple adenocarcinomas still remains unclear.
  • We herein examined the EGFR mutations in 9 AAH and 31 adenocarcinoma lesions obtained from 30 Japanese patients.
  • Nine patients had synchronous or metachronous multiple adenocarcinomas and/or AAH.
  • EGFR mutations were detected in 4 (44%) of 9 AAH and in 7 (23%) of 31 adenocarcinomas.
  • A gefitinib-resistant point mutation (T790M) in exon 20 without gefitinib treatment was detected in 1 AAH and 1 adenocarcinoma.
  • The patient with T790M mutated AAH, which also had an exon 19 mutation of D761Y, had synchronous adenocarcinoma, which had only an exon 19 mutation of D761Y.
  • In the two patients with synchronous AAH and adenocarcinoma, AAH had mutations at exon 19 although adenocarcinoma did not have any mutations.
  • In the patient with synchronous 2 adenocarcinomas, each had different mutations (exons 19 and 21).
  • In two patients with double adenocarcinomas, 1 adenocarcinoma harbored exon 21 mutations, while the other demonstrated no mutations.
  • Although EGFR mutations appeared to be partially associated with the early steps of adenocarcinoma development, such mutations may possibly occur randomly even in multiple lesions in a single patient.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatosis, Pulmonary / genetics. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Neoplasms, Multiple Primary / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561305.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


30. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, Matsuo K, Otani H, Jida M, Kubo T, Tsukuda K, Kiura K, Sano Y, Date H: Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol; 2008 Jul;3(7):704-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
  • OBJECTIVE: The purpose of this study was to identify risk factors for poor clinical outcome after surgical resection of small lung adenocarcinoma.
  • MATERIALS AND METHODS: Clinical records of 127 patients who had pathologic stage IA lung adenocarcinoma 20 mm or less and who had undergone a lobectomy with mediastinal lymph node dissection were reviewed.
  • The percentage of non-bronchioloalveolar carcinoma (non-BAC) components quantified objectively, and epidermal growth factor receptor gene (EGFR) mutation determined by polymerase chain reaction-based assay were retrospectively linked with clinical data.
  • RESULTS: Based on the percentage of non-BAC component, 127 patients were classified as follows: 26 in group I, BAC, 46 in group II mixed subtype with >or= 50% BAC, 18 in group III, mixed subtype with under 50% BAC, and 37 in group IV, mixed subtype with all non-BAC components or a pure pattern of one of the non-BAC components.
  • Groups I and II were considered to be a "low non-BAC component type" and groups III and IV were considered to be a "high non-BAC component type."
  • In terms of recurrence, the high non-BAC component type was the only independent factor for recurrence (p = 0.029).
  • Regarding survival, the high age (p = 0.028) and high non-BAC component type (p = 0.046) were independent risk factors for poor overall survival.
  • CONCLUSION: The high non-BAC component but not EGFR mutation status, is an independent risk factor for both recurrence and poor prognosis in patients with stage IA lung adenocarcinoma <or=20 mm.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology. Mutation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18594314.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Proctor L, Folpe AL, Esper A, Wolfenden LL, Force S, Logani S: Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fine-needle aspiration with emphasis on use of beta-catenin as a useful diagnostic marker. Diagn Cytopathol; 2007 Jan;35(1):39-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated fetal adenocarcinoma of the lung: cytomorphologic features on fine-needle aspiration with emphasis on use of beta-catenin as a useful diagnostic marker.
  • Well-differentiated fetal adenocarcinoma (WDFA), also known as low grade adenocarcinoma of the fetal lung type, is a rare pulmonary neoplasm now considered to be a variant of lung adenocarcinoma rather than a type of pulmonary blastoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. beta Catenin / analysis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoid Tumor / pathology. Carcinoma / secondary. Cell Nucleus / chemistry. Cell Nucleus / pathology. Colorectal Neoplasms / secondary. Cytoplasm / chemistry. Cytoplasm / pathology. Diagnosis, Differential. Endometrial Neoplasms / secondary. Female. Humans. Pulmonary Blastoma / chemistry. Pulmonary Blastoma / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173289.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


32. Shomura H, Nakano S, Funai T, Akabane H, Inagaki M, Yanagida N, Kudo T, Orimo T, Oikawa F, Emoto S, Yoneya R: [A case of metastasis to the stomach from primary adenocarcinoma of the lung cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2481-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastasis to the stomach from primary adenocarcinoma of the lung cancer].
  • We report a case of gastric metastasis of lung cancer performed gastrectomy for the primary foci.
  • A 70s woman was diagnosed as having right lung cancer and underwent right lower lobectomy and lymph node dissection.
  • The histological diagnosis was adenocarcinoma (pT4, N2, M0).
  • Biopsy showed a papillary adenocarcinoma.
  • With the diagnosis of gastric metastasis from lung cancer, she was operated on.
  • The histopathological examination demonstrated papillary adenocarcinoma similar to that of the lung cancer with lymph node metastasis.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224613.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Fukui T, Tsuta K, Furuta K, Watanabe S, Asamura H, Ohe Y, Maeshima AM, Shibata T, Masuda N, Matsuno Y: Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci; 2007 Nov;98(11):1714-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung.
  • In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC).
  • We retrospectively studied six patients with combined SCLC with Ad components among 64 consecutive patients who underwent resection of SCLC.
  • The clinicopathological features of each patient were reviewed, especially for the distribution pattern of the Ad component and lymph node metastases.
  • EGFR mutations were screened by high-resolution melting analysis in each case, and were confirmed by sequencing of each mutation in the microdissected SCLC or Ad components.
  • In this case, both the SCLC and Ad components shared the same mutation in exon 21 (L858R).
  • We identified a patient with combined SCLC with Ad sharing an identical EGFR mutation in both the SCLC and Ad components.
  • In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17784875.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


34. Ebi N, Semba H, Tokunaga S, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine S, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu (LOGIK): Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e19059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis.
  • : e19059 Background: Lung cancer is a disease of the elderly with median age at diagnosis of 70 yrs.
  • Patient characteristics: male/female = 12/16, median age = 82 (range 80-90), ECOG PS 0/1/2=7/13/8, stage IB/IIIA/IV=1/3/24, and adenocarcinoma (Ad)/non-Ad= 22/6.
  • There were two pts with possible interstitial lung disease including one treatment-related death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962159.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Girvan AC, Peltz G, Pennella E, Pohl G, Faries D, Marciniak MD, Obasaju CK, Stepanski EJ, Schwartzberg LS, Adjei AA: An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans. J Clin Oncol; 2009 May 20;27(15_suppl):e20624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans.
  • : e20624 Background: African-Americans are more likely to develop and die from lung cancer than persons of any other ethnic group.
  • This prospective, single-arm, observational study evaluates the impact of ethnicity on disease control rate (DCR) (CR + PR + SD)) in patients (pts) with non-small lung cancer (NSCLC) being treated with pemetrexed (Pem) in the second-line setting.
  • Demographics of Caucasians: M/F (136:107); median age 66 (range 37-88); histology adenocarcinoma/squamous/other/unknown (141:67:33:2).
  • Demographics of African-Americans: M/F (21:13); median age 64 (range 43-80); histology adenocarcinoma/squamous/other/unknown (22:9:3:0).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Cao W, Zhang D, Qiao J, Fang C, Hou R: [Expression and its significance of Pin1 and β-catenin in squamous cell carcinoma and adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):418-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and its significance of Pin1 and β-catenin in squamous cell carcinoma and adenocarcinoma of the lung].
  • The aim of this study is to explore the relationship between the expression of Pin1 and clinicopathological factors in squamous cell carcinoma and adenocarcinoma of the lung, and to analyze the correlation between Pin1 and β-catenin.
  • METHODS: The expression of Pin1 and β-catenin proteins was detected in 69 lung cancer cases by immunohistochemical SP method, and in 30 fresh lung samples by Western blot.
  • RESULTS: Immunohistochemically, the overexpression of Pin1 and β-catenin in lung cancer was 78.3% (54/69) and 63.8% (44/69), respectively.
  • Western blot results showed that the expression of Pin1 and β-catenin in lung cancer tissues was significantly higher than that of paracancerous lung tissues (P < 0.05).
  • CONCLUSIONS: Pin1 is overexpressed in squamous cell carcinoma and adenocarcinoma of the lung and may play a critical role in oncogenesis of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176462.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K: Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol; 2010 Aug;5(8):1136-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung.
  • INTRODUCTION: The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene is one of the most intriguing recent discoveries in the field of lung cancer research, and they are more commonly found in adenocarcinoma occurring in females, never/light smokers, and East Asian patients.
  • METHODS: This study evaluated the medical records of 437 patients with adenocarcinoma of the lung who underwent a surgical resection.
  • In females, the incidences of EGFR mutation were 61.0% and 41.7% in HLA-A2 (+) and A2 (-) patients with adenocarcinoma of the lung, respectively (p = 0.008).
  • CONCLUSIONS: EGFR: mutations are associated with HLA-A2 in female patients with adenocarcinoma of the lung.
  • Further research was needed to elucidate the other relevant factors in the histogenesis of lung cancer with an EGFR mutation.
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group / genetics. Histocompatibility Antigens / genetics. Lung Neoplasms / genetics. Mutation / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Alleles. DNA / genetics. Female. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20548248.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 9007-49-2 / DNA; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Nakazono T, Sakao Y, Yamaguchi K, Imai S, Kumazoe H, Kudo S: Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT. Eur Radiol; 2005 Aug;15(8):1563-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT.
  • The purpose of this study was to scrutinize morphological characteristics of thin-section CT of the histopathological subtypes of adenocarcinoma of the lung.
  • The subjects consisted of 83 patients with 87 adenocarcinomas measuring 3 cm or less in the largest.
  • We believe thin-section CT findings reflect the histopathological subtypes of adenocarcinoma of the lung.
  • The presence of air bronchogram and bubble-like areas of low attenuation areas in particular is useful to differentiate replacement growth tumors from non-replacement growth tumors.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Female. Humans. Lung / diagnostic imaging. Lung / pathology. Male

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur Radiol. 2006 May;16(5):1185
  • [Cites] Eur Radiol. 2004 Jan;14 (1):86-92 [14615902.001]
  • [Cites] Eur Radiol. 2004 Apr;14 (4):691-702 [14727146.001]
  • [Cites] Ann Thorac Surg. 2003 Apr;75(4):1113-7 [12683547.001]
  • [Cites] Radiology. 1991 May;179(2):469-76 [2014294.001]
  • [Cites] Eur Radiol. 2004 May;14 (5):897-901 [14666377.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):763-8 [10701622.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):465-9 [10430155.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1163-70 [8313318.001]
  • [Cites] Eur Radiol. 2004 Jul;14 (7):1226-33 [15029450.001]
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1071-5 [11996243.001]
  • [Cites] Lung Cancer. 2001 Jul;33(1):17-25 [11429192.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1802-13 [6478416.001]
  • (PMID = 15846496.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


39. Myint R, Batus M, Bonomi P, Gattuso P, Warren WH, Liptay M, Faber P, Basu S, Xu X, Kim AW: Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthine oxidoreductase and chemosensitivity in non-small cell lung cancer.
  • Clin Cancer Res.
  • The goal of our study was to show that decreased XOR expression was associated with decreased survival in non-small cell lung cancer (NSCLC).
  • These included 41 adenocarcinoma, 31 squamous cell, 8 poorly/moderately differentiated, and 2 bronchioloalveolar.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963201.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, Nowicki ER, Mekhail TM, Mason DP, Rice TW, Blackstone EH: Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg; 2010 Oct;90(4):1067-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung.
  • BACKGROUND: Understanding recurrence of surgically "cured" stage I adenocarcinoma of the lung is important given expected benefits of adjuvant therapy for advanced disease.
  • Therefore, this study characterizes cancer recurrence and its risks, assesses survival after recurrence, and contextualizes overall survival and its risks.
  • METHODS: From 1991 to 2001, 285 patients underwent resection of stage I adenocarcinoma (pathologic) of the lung.
  • They were followed cross-sectionally for evidence of cancer recurrence (mean follow-up 7.7 ± 4.3 years).
  • Risk factors for recurrence and all-cause mortality were sought among demographic, medical history, cancer pathology, and surgical procedure data.
  • RESULTS: Cancer recurred in 99 patients.
  • Overall survival (65% and 40% at 5 and 10 years) depended not only on variables related to cancer recurrence, but also those of vitality (older age, pulmonary dysfunction, postpneumonectomy state).
  • CONCLUSIONS: Stage I adenocarcinoma of the lung recurs.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymph Nodes / pathology. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20868788.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Castro C, Cardona AF, Reguart N, Carrasco-Chaumel E, Otero JM, Carranza H, Vargas C, Reveiz L, Torres D, Blumenschein G: Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated advanced lung adenocarcinoma (ALA) patients (pts) (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e19052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated advanced lung adenocarcinoma (ALA) patients (pts) (ONCOLGroup study).
  • : e19052 Background: There is consistent information suggesting that long-term WSE constitutes a risk factor for lung cancer.
  • More than 50 years of WSE was associated with non-small cell lung cancer (NSCLC).
  • Retrospectively, we estimated overall response rates (ORR), time to progression (TTP) and overall survival (OS) in a subgroup of pts with significant WSE (exposure >5 years for at least 4 hours/day) treated with erlotinib, and compared them with the non-WSE population treated with the same compound.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962158.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Goto K, Kenmotsu H, Nishiwaki Y, Kubota K, Ohmatsu H, Niho S, Yoh K, Nagai K, Saijo N: Current trend in incidence of severe interstitial lung disease (ILD) due to gefitinib in Japan. J Clin Oncol; 2009 May 20;27(15_suppl):e19075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current trend in incidence of severe interstitial lung disease (ILD) due to gefitinib in Japan.
  • : e19075 Background: Although gefitinib is a promising agent for the treatment of advanced non-small cell lung cancer, ILD occurs in Japanese patients and sever ILD sometimes becomes fatal toxicity.
  • On the other hand, it has been reported that female gender, adenocarcinoma, non-smoker, and EGFR mutation are associated with sensitivity to gefitinib.
  • METHODS: To investigate the trend in incidence of severe ILD and patient characteristics receiving gefitinib, a total of 751 patients who were administered gefitinib in National Cancer Center Hospital East between 2002 and 2008 were retrospectively reviewed.
  • In these patients, percentages of female were 36/43/42/55/59/52/54%, adenocarcinoma 76/78/93/88/95/93/92%, non-smoker 35/30/40/53/49/48/46%, respectively.
  • Almost all of the patient receiving gefitinib was recently restricted to adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962212.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Yoshimi R, Takeno M, Yamanaka S, Shiina M, Kirino Y, Takeda Y, Sekiguchi A, Kobayashi H, Ihata A, Motoji K, Ohno S, Ueda A, Soga T, Ishigatsubo Y: Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung. Mod Rheumatol; 2006;16(3):165-8
MedlinePlus Health Information. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung.
  • In the postmortem examination, the tumor was pathologically diagnosed as pseudomesotheliomatous adenocarcinoma (PMA) of the lung, classified into pleomorphic carcinoma with adenocarcinoma component according to the new World Health Organization guidelines.

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767555.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Xu H, Wang G, Ma L, Qi F, Liu Y, Yu J, Dai S, Wang E: [Expression of STK15 and its significance in squamous cell carcinoma and adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006 Jun 20;9(3):259-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of STK15 and its significance in squamous cell carcinoma and adenocarcinoma of the lung].
  • The overexpression of STK15 is significantly associated with carcinogenesis in many tumors, however, its expression and significance in human lung cancer are still unclear.
  • The aim of this study is to investigate the expression of STK15 in squamous cell carcinoma and adenocarcinoma of the lung and to analyze the correlation between STK15 expression and clinicopathological factors.
  • METHODS: The pattern of STK15 protein expression was detected in 44 squamous cell carcinomas, 36 adenocarcinomas and 20 paracancerous lung tissue samples by immunohistochemistry method using anti-STK15 antibody.
  • The relative quantity of STK15 protein expression was detected by Western blot, and STK15 mRNA expression was detected by RT-PCR in 40 fresh lung cancer samples and corresponding paracancerous lung tissues.
  • RESULTS: Positive expression rate of STK15 protein was 68.75% (55/80) in lung cancer tissues and 0% in paracancerous controls (P < 0.001).
  • STK15 expression was significantly related to differentiation grade of lung cancer (P=0.011), but not to histological classification, TNM stages or lymphatic metastasis (P > 0.05).
  • The relative expression levels of STK15 protein (P < 0.001 ) and STK15 mRNA (P < 0.001) in lung cancer tissues were both significantly higher than those of corresponding paracancerous lung tissues.
  • CONCLUSIONS: The expression of STK15 protein and STK15 mRNA is significantly higher in lung cancer tissues than that in paracancerous lung tissues.
  • The expression of STK15 correlates with differentiation of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21172157.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Shim SS, Lee KS, Kim BT, Choi JY, Shim YM, Chung MJ, Kwon OJ, Lee EJ: Integrated PET/CT and the dry pleural dissemination of peripheral adenocarcinoma of the lung: diagnostic implications. J Comput Assist Tomogr; 2006 Jan-Feb;30(1):70-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated PET/CT and the dry pleural dissemination of peripheral adenocarcinoma of the lung: diagnostic implications.
  • OBJECTIVE: The aim of this study was to describe retrospectively the CT findings of dry pleural dissemination of peripheral lung adenocarcinoma, and to compare the mutual roles of PET and CT components of integrated PET/CT in the diagnosis of the disease.
  • METHODS: The authors analyzed retrospectively the CT findings of pathologically proved dry pleural dissemination in 8 of 172 patients with peripheral adenocarcinoma of the lung.
  • Subsequently, one radiologist and one nuclear medicine physician (unaware of the CT and pathologic results) evaluated together in a random order the integrated PET/CT of 172 adenocarcinoma patients (8 with dry pleural dissemination and 164 without).
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Tomography, Emission-Computed. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Contrast Media. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Iopamidol. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365577.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; JR13W81H44 / Iopamidol
  •  go-up   go-down


46. Feliu J, Safont M, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, González-Barón M: Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma.
  • : 4119 Background: Colorectal adenocarcinoma is the most common cancer in subjects over 70 years old.
  • The aim of the present study is to evaluate the overall response rate in that patient's population who presents colorectal adenocarcinoma and are treated with the combination of capecitabine+BVZ.
  • METHODS: This is a multicentric, non-controlled, open label, phase II clinical trial.
  • Metastases were detected in liver (84.7%), lung (45.8%), local/regional (18.6%) and other locations (5.1%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961217.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Kim D, Lee S, Lee J, Lee M, Kang J, Kim S, Shin S, Kim H, Heo DS: A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutations. J Clin Oncol; 2009 May 20;27(15_suppl):8066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II study to evaluate efficacy and safety of gefitinib as the first-line treatment for Korean patients (pts) with advanced pulmonary adenocarcinoma harboring EGFR mutations.
  • : 8066 Background: This study (D7913L00056) was designed to prospectively evaluate the efficacy and safety of first-line gefitinib treatment in pts with advanced pulmonary adenocarcinoma harboring EGFR mutations and to explore the molecular factors affecting the efficacy of gefitinib.
  • METHODS: Chemo-naïve pts with advanced (stage IIIB/IV/recurrent disease) pulmonary adenocarcinoma underwent direct DNA sequencing of tumor EGFR exons 18, 19 and 21.
  • The most common EGFR mutations were in-frame exon 19 deletions (del 19, 29 pts, 64%) and L858R point mutations in exon 21 (L858R, 15 pts, 33%).
  • The ORR and DCR were higher in pts with del 19 than those with L858R (62.1% vs 33.3%; P=0.0705 and 96.6% vs 66.7%; P=0.0062, respectively).
  • In addition, PFS at 12 mo was significantly better in pts with del 19 than those with L858R (63.2% vs 23.8%, P=0.0034).
  • CONCLUSIONS: Gefitinib as the first-line treatment for Korean pts with advanced pulmonary adenocarcinoma harboring EGFR mutations was very effective and well tolerated.
  • Subgroup analysis suggests that the benefit from gefitinib treatment was more prominent in pts with the del 19 mutation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Venkata C, Mireles JA, Venkateshiah SB: Refractory hypoxemic respiratory failure due to adenocarcinoma of the lung with predominant bronchioloalveolar carcinoma component. Respir Care; 2009 Nov;54(11):1496-9
MedlinePlus Health Information. consumer health - Respiratory Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory hypoxemic respiratory failure due to adenocarcinoma of the lung with predominant bronchioloalveolar carcinoma component.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / complications. Anoxia / etiology. Lung Neoplasms / complications. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863835.001).
  • [ISSN] 0020-1324
  • [Journal-full-title] Respiratory care
  • [ISO-abbreviation] Respir Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Gong Y, Yao E, Arcila M, Frankel S, Teruya-Feldstein J, Zakowski M, Thomas R, Ladanyi M, Pao W: Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). J Clin Oncol; 2009 May 20;27(15_suppl):8095

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8095 Background: The IGF-1R (IGF receptor type 1) pathway is frequently deregulated in human tumors and has become a target of interest for anti-cancer therapy.
  • METHODS: We examined the growth inhibitory effects of R1507, a fully-humanized IgG1 anti-IGF-1R monoclonal Ab (Roche), against a panel of 22 NSCLC cell lines using CellTiter Blue assays.
  • RESULTS: 5 of 22 NSCLC cell lines were moderately sensitive (25-50% growth inhibition) to R1507 alone.
  • In one EGFR mutant lung adenocarcinoma cell line, R1507 and erlotinib co-treatment induced apoptosis, whereas treatment with either drug alone induced only cell cycle arrest.
  • CONCLUSIONS: In NSCLC cell lines, high levels of total IGF-1R are associated with moderate sensitivity to R1507.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962673.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Hasegawa S, Fukuoka K, Nakano T: Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer.
  • : 11066 Background: Circulating tumor cell (CTC), a surrogate of distant metastasis, and circulating endothelia cell (CEC), a surrogate of angiogenesis, are potentially useful in the diagnosis of malignant tumors, but clinical significance of CTC/CEC in primary lung cancer (LC) remains unclear.
  • RESULTS: In 42 (30.7%) of 137 LC cases, CTC in the peripheral blood was positive (CTC-count, more than 1 cell/7.5mL), and the maximum CTC-count was 62 cells.
  • In 11 (18.3%) of 145 cases with non-malignant (NM) diseases, CTC was also positive; however, in NM cases, CTC-count was 1 (cell/7.5mL) in most CTC-positive cases and the maximun CTC-count was 2.
  • Among LC cases, the incidence of case with CTC-positive (CTC-count, 1 or more) was highest in small cell carcinoma cases (7/10, 70.0%), followed by squamous cell carcinoma (9/22, 40.9%) and adenocarcinoma (23/94, 24.5%) cases; the incidence of CTC-positive case was significantly higher in stage IV cases (68.6%; p<0.001), but it should be noted that CTC was positive in 17.4% of stage I cases and 15.4% of stage II cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Fabre E, Medioni J, Dosset M, Dosset M, Tartour E, Oudard S, Riquet M, Adotevi O: T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • : 3061 Background: hTERT is a potential target for cancer immunotherapy because it is highly expressed in tumor cells.
  • Thereafter, we analyzed its link with age (< 60 vs. ≥ 60 yrs), ECOG performance status PS (0-1 vs. 2-3), tumoral stage (III vs. IV), histological subtype (adenocarcinoma vs. other), and smoking status (never smoker vs. smoker).
  • Eighteen pts presented anti-hTERT T lymphocytes (54%); among them we found 12 pts ≥ 60 yrs (70%), 14 adenocarcinoma (77%), 13 stage IV (72%), 7 pts with PS 2/3 (41%), and 13 smokers (72%).
  • So far, univariate analysis showed no relationship between presence of anti-hTERT T-cell responses and pts' characteristics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Kosty MP, Kumar P, Wozniak A, Jahanzeb M, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):e19045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS).
  • Severe (≥grade 3) pulmonary hemorrhage (sPH) is a rare but serious event that has been associated with BV-based therapy in phase 3 trials (rate of 2-4%).
  • Key BL characteristics for the substudy and overall cohorts, respectively, include: 44% vs 51% ≥65 yrs; 67% vs 67% adenocarcinoma; 6% vs 5% therapeutic AC.
  • The final analysis of an ARIES Lung substudy assessing on-study development of cavitation and association with sPH will be presented at the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Yang C, Hirsh V, Cadranel J, Chen Y, Park K, Kim S, Chao T, Oberdick M, Shahidi M, Miller V: Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX- Lung1): A preliminary report. J Clin Oncol; 2009 May 20;27(15_suppl):8062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with advanced adenocarcinoma of the lung (Stage IIIB/IV; ECOG 0-2), who have failed one or two lines of CT (including platinum) and progressed following at least 12 weeks of E or G are randomized in a 2:1 ratio to receive BSC plus either oral BIBW 2992 50 mg qd or placebo until disease progression or unacceptable toxicity.
  • Main prior EGFR-TKI was G in Asians (70%) and E in non-Asians (85%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962637.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Kim ES, Herbst RS, Lee JJ, Blumenschein G, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, Hong WK: Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol; 2009 May 20;27(15_suppl):8024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program.
  • 112 of the biopsied lesions were lung, with a pneumothorax rate of 12.1% (15 of 124 pts; grade 1-2 only; lung, mediastinal and pleural sites).
  • HISTOLOGY: adenocarcinoma (75%), squamous (11%), large cell (13%).
  • BATTLE is one of the first studies in advanced lung cancer to prospectively utilize biomarker analysis of fresh biopsies to direct pt treatment, and is a step towards personalizing therapy in NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962837.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Shabbir M, Daniels L, Shirai K, Cole S, Willey J, Iovino L, Labarre K, Green MR: Prescribing plans (PP) of American Oncologists for first-line therapy (Rx) for patients with stage III (wet)/IV non-small cell lung cancer (NSCLC) and PS 2: Overall selection and impact of gender and smoking status. J Clin Oncol; 2009 May 20;27(15_suppl):e19046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prescribing plans (PP) of American Oncologists for first-line therapy (Rx) for patients with stage III (wet)/IV non-small cell lung cancer (NSCLC) and PS 2: Overall selection and impact of gender and smoking status.
  • METHODS: Between February '07 and October '08, we used a core case scenario of stage IV mucin positive adenocarcinoma (Adeno ca) of lung in a 68-year-old former smoker (FS; stopped 6 years ago) with PS 2, to study patient related variations in PP of almost 800 American medical oncologists during 10 live research events [393 MDs/5 events during 2008].
  • The impact of recently reported progression free survival data from an Asian phase III trial (IPASS: gefitinib or chemotherapy or as 1<sup>st</sup>-line therapy in non or former light-smoking patients with lung adenoca) on future prescribing plans in this clinical setting will be of great interest.
  • CONCLUSIONS: By our observations, smoking status dominates over gender in PP of oncologists when treating wet IIIB/IV Adeno ca of lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Kayali F, Janjua MA, Laber DA, Miller DM, Day JM, Kloecker GH: Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC).
  • : e19077 Background: There is laboratory evidence that digoxin sensitizes cancer cells to the induction of apoptosis by chemotherapy.
  • Inhibition of the Na/K-ATPase enzyme by ouabain disturbs the intracellular ion composition of cancer cells, altering cellular homeostasis.
  • Epidemiologic studies also have shown beneficial effects of digitalis in breast cancer incidence.
  • All patients had unresectable stage III/IV at diagnosis.
  • Histologies were 50% adenocarcinoma, 30% squamous and 20% unspecified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962216.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Sekine I, Sumi M, Ito Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of concurrent high-dose three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).
  • Of these, 23 (74%) had adenocarcinoma and 20 (65%) had stage IIIA disease.
  • Grade 4 infection, grade 3 esophagitis and grade 3 pulmonary toxicity were noted in one, two and one patients, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963322.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Pennell NA, Videtic GM, Murthy S, Mason D, Rice TW, Mazzone P, Samsa J, Rich T, Shapiro M, Mekhail T: A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC).
  • Non-progressors underwent resection followed by the same CRT regimen and 2 years of mE (150mg).
  • 25 pts were treated in the phase II component: median age 60, 92% stage IIIA, 64% female, 72% PS 0, 64% adenocarcinoma, and 16% never smokers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Arifin M, Hiyama K, Tanimoto K, Wiyono WH, Hiyama E, Nishiyama M: EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. Oncol Rep; 2007 Jun;17(6):1405-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung.
  • The prognosis of lung cancer remains poor, and biological heterogeneity is largely responsible, especially in adenocarcinoma.
  • We previously found that only one third of non-small cell lung cancer (NSCLC) but most small cell lung cancer (SCLC) tissues have strong telomerase activity, representing the difference in the history of multiple clonal selections.
  • To reveal the genes differentially involved in telomerase activation mechanisms, we analyzed the relationship between common genetic aberrations and telomerase activity in 83 lung cancer tissues.
  • We found that half (7 of 14) of lung adenocarcinomas with high telomerase activity showed neither TP53 nor RB1 deletion, while all squamous cell carcinomas and SCLCs with high telomerase activity showed loss of heterozygosity of at least one, if not both, of these suppressor oncogenes, indicating that these genetic aberrations are not required in activation of telomerase in a unique subset of adenocarcinoma.
  • Furthermore, whereas the aberrations in TP53, RB1 and 1p34-pter were mutually related in 42 adenocarcinoma tissues, EGFR aberrations showed no relationship to either of them.
  • These findings indicate that EGFR activating aberrations occur independently of other common genetic aberrations or telomerase activation mechanisms in lung adenocarcinoma, and that the distinct subset of lung adenocarcinoma with high telomerase activity without any common genetic aberrations may possibly have arisen from a telomerase-positive or telomerase-competent normal cell.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487398.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.7.49 / Telomerase; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


60. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS: A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol; 2010 Jul;5(7):1054-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
  • INTRODUCTION: Aflibercept (vascular endothelial growth factor [VEGF] trap), a recombinant fusion protein, blocks the activity of VEGF-A and placental growth factor and has demonstrated activity in pretreated patients with lung cancer in a phase I trial.
  • This study evaluated the efficacy and safety of intravenous aflibercept in patients with platinum- and erlotinib-resistant lung adenocarcinoma.
  • Patients with platinum- and erlotinib-resistant lung adenocarcinoma were eligible.
  • CONCLUSIONS: Aflibercept has minor single agent activity in heavily pretreated lung adenocarcinoma, and is well tolerated, with no unexpected toxicities.
  • Further studies evaluating aflibercept in lung cancer, in combination with chemotherapy and other targeted therapies, are ongoing.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Resistance, Neoplasm. Lung Neoplasms / drug therapy. Recombinant Fusion Proteins / therapeutic use. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593550.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Recombinant Fusion Proteins; 15C2VL427D / aflibercept; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


61. Basu S, Alavi A: Cardiac involvement from adenocarcinoma of the lung at diagnosis detected by (18)F-FDG-PET imaging. Hell J Nucl Med; 2008 Sep-Dec;11(3):182
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement from adenocarcinoma of the lung at diagnosis detected by (18)F-FDG-PET imaging.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Heart Neoplasms / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081865.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. But Hadzic J, Secerov A, Zwitter M, Lamovec J, Kern I, Kavsek G, Hergouth KM, De Greve J: Metastatic adenocarcinoma of the lung in a 27-year-old pregnant woman. J Thorac Oncol; 2007 May;2(5):450-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the lung in a 27-year-old pregnant woman.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Metastasis. Pregnancy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2007 Jul;2(7):676
  • (PMID = 17473662.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hudson E, Lester JF, Attanoos RL, Linnane SJ, Byrne A: Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung. J Pain Symptom Manage; 2006 Sep;32(3):200-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Bronchial Diseases / diagnosis. Bronchial Diseases / drug therapy. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Octreotide / therapeutic use

  • MedlinePlus Health Information. consumer health - Bronchial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939841.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


64. Massuti B, Morán T, Porta R, Queralt C, Cardenal F, Mayo C, Camps C, Majem M, Tarón M, Rosell R: Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol; 2009 May 20;27(15_suppl):8023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial.
  • EGFR mutations were detected in 358 p; 217 were entered on the trial: 158 (72.8%) female; 148 (68.2%) never-smokers; 176 (81.1%) adenocarcinoma; 134 (62.3%) exon 19 deletion, 83 (37.7%) L858R mutation; 112 (51.6%) first-line, 104 (48.4%) second-line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962803.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Hatoum HA, Habib JG, Tawil A, Chakhachiro Z, Otrock ZK, Husari A, Shamseddine A: Adenocarcinoma of the lung presenting as a metastatic tongue mass. South Med J; 2008 Jul;101(7):770-1
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the lung presenting as a metastatic tongue mass.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Tongue Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209120.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


66. Van Hul I, Cools P, Rutsaert R: Solitary splenic metastasis of an adenocarcinoma of the lung 2 years postoperatively. Acta Chir Belg; 2008 Jul-Aug;108(4):462-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic metastasis of an adenocarcinoma of the lung 2 years postoperatively.
  • We report a case of an asymptomatic, isolated splenic metastasis in a 67-year-old man diagnosed 2 years after resection of an adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Laparotomy. Male. Pneumonectomy. Splenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807605.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


67. Farley R, Manolidis S, Ratner D: Adenocarcinoma of the lung metastatic to the skull presenting as a scalp cyst. J Am Acad Dermatol; 2006 May;54(5):916-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the lung metastatic to the skull presenting as a scalp cyst.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Cysts / diagnosis. Lung Neoplasms / pathology. Scalp / pathology. Skull Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635687.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


68. Zhu Y, Chen L: Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22230

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of SP cells in human lung adenocarcinoma SPC-A1 cells.
  • With an extensive understanding of their biology, a major role for stem cells in the malignant process has been proposed and the existence of cancer stem cells(CSCs) has been confirmed in hematopoietic malignancies, brain cancer, and solid organ malignancies including breast, prostate, colon, and pancreatic cancer.
  • Lung cancer is the leading cause of cancer mortality in most large cities of China.
  • It is possible that lung cancer contains cancer stem cells responsible for its malignancy.
  • The aim of this study is to identify, characterize and enrich the CSC population that drives and maintains lung adenocarcinoma growth and metastasis.
  • METHODS: Side population (SP) cell analysis and sorting were applied to established human lung adenocarcinoma cell line and an attempt to further enrich them by preliminary serum-free culture before fluorescence activated cell sorting(FACS) was done.
  • Stem cell properties of SP cells were evaluated by their proliferative index, colony-forming efficiency, tumorigenic potential, bi-differentiation capacity and the expression of common stem cell surface markers.
  • RESULTS: Lung cancer cells could grow in a serum-free Medium (SFM) as non-adherent spheres similar to neurospheres or mammospheres.
  • The proportion of SP cells in cell spheres was significantly higher than that in cells grown as monolayers.
  • SP cells were both CCA positive and SP-C positive while non-SP cells were only SP-C positive.
  • Flow cytometric analysis of cell phenotyping showed that SP cells expressed CD133 and CD44, the common cell surface markers of cancer stem cells, while non-SP cells only expressed CD44.
  • CONCLUSIONS: SP cells existed in human lung adenocarcinoma cell lines and they could be further enriched by preliminary serum-free culture before FACS sorting.
  • SP cells possessed the properties of cancer stem cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964107.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gutiérrez-Santiago M, Rodríguez-Cobo V, Riancho JA: [Aromatase-dependent gynecomastia in a patient with adenocarcinoma of the lung]. Med Clin (Barc); 2005 Oct 15;125(13):518-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aromatase-dependent gynecomastia in a patient with adenocarcinoma of the lung].
  • [Transliterated title] Adenocarcinoma pulmonar con ginecomastia dependiente de aromatasa.
  • [MeSH-major] Adenocarcinoma / complications. Gynecomastia / etiology. Lung Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238933.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase
  •  go-up   go-down


70. Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M: Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer; 2009 Sep;65(3):383-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
  • A 53-year-old woman was with adenocarcinoma of the lung metastatic to the brain was treated after several lines of chemotherapy with pemetrexed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375814.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


71. Meng X Jr, Yu JM, Yang GR, Zhao SQ, Sun XD: &lt;sup&gt;11&lt;/sup&gt;C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy. J Clin Oncol; 2009 May 20;27(15_suppl):7576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] <sup>11</sup>C-PD153035 PET/CT molecular imaging of EGFR for evaluation of advanced non-small cell lung cancer (NSCLC) to EGFR-targeted therapy.
  • : 7576 Background: Our previous study suggests that <sup>11</sup>C-PD153035, a specific and potent inhibitor of EGFR tyrosine kinase (EGFR-TKI), is a novel PET radiotracer and <sup>11</sup>C-PD153035 PET/CT is a promising non-invasive method for in vitro and vivo imaging of EGFR in NSCLC.
  • RESULTS: 12 patients (5 men, 7 women; age range, 60-79 years) have been enrolled in this study from August 2008, including 3 cases of squamous cell carcinoma, 1 case of large cell carcinoma, and the other of adenocarcinoma.
  • Tumor/lung ratio at 20 min was 4.14 ± 1.80.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963384.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Oizumi S, Akie K, Ogura S, Shinagawa N, Fukumoto S, Harada M, Kojima T, Kinoshita I, Dosaka-Akita H, Isobe H, Nishimura M: Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601. J Clin Oncol; 2009 May 20;27(15_suppl):e19012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group 0601.
  • : e19012 Background: Platinum-containing therapy is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC).
  • Median age was 64 years (range, 42-75); 29 patients (73%) had adenocarcinoma, and 8 patients (20%) had squamous cell carcinoma.
  • The most common non-hematologic toxicities of grade 3 or 4 included diarrhea (15.0%) and anorexia (17.5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, Watanabe N, Sakamoto J, Aoe M, Date H: A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses. J Clin Oncol; 2009 May 20;27(15_suppl):7560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): Planned interim analyses.
  • Sixty patients had adenocarcinoma, 30 had squamous cell carcinoma, and 10 had other histologies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963337.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Motoyama S, Ogawa J: Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Tumour Biol; 2010 Oct;31(5):533-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
  • Inhibition of histone deacetylases (HDACs) is a promising new approach to the treatment of lung cancer therapy.
  • The relation between HDAC3 expression and the clinicopathological characteristics of lung cancer is not well understood, however.
  • We therefore addressed this issue in patients with adenocarcinoma of the lung.
  • We used semi-quantitative real-time reverse transcription polymerase chain reaction and immunohistochemical analysis to assess expression of HDAC3 in tumor samples from 94 patients with adenocarcinoma of the lung.
  • Strong tumoral expression of HDAC3 is an independent predictor of a poor prognosis in patients with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Histone Deacetylases / biosynthesis. Lung Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20563766.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


75. Song X, Song Z, Lv Y, Zhong M, Li X: [The Study on Gene Amplification of EGFR in Bronchioloalveolar Carcinoma and Conventional Adenocarcinoma of the Lung.]. Zhongguo Fei Ai Za Zhi; 2009 Aug 20;12(8):879-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Study on Gene Amplification of EGFR in Bronchioloalveolar Carcinoma and Conventional Adenocarcinoma of the Lung.].
  • BACKGROUND: Patients with adenocarcinoma of the lung have disproportionately response to the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
  • The aim of this study is to analyze the difference of EGFR gene amplification in bronchioloalveolar carcinoma (BAC), adenocarcinma mixed subtype and conventional adenocarcinoma of the lung and provide some information to clinical therapies.
  • METHODS: Lung cancer cases were collected and reviewed from the archives of the Department of Pathology, Chinese PLA General Hospital during the time period from 2004 to 2006.
  • The definite diagnosis of BAC based on 2004 WHO classification of lung tumors was made by two pathologists.
  • Fluorescence in situ hybridization (FISH) was performed to detect EGFR gene amplification in pure BAC, adenocarcinma mixed subtype and conventional adenocarcinoma.
  • RESULTS: Conventional adenocarcinoma had higher EGFR amplification compared with pure BAC and adenocarcinma mixed subtype (Chi-square=11.632, P<0.05).
  • EGFR gene amplification was found in 45.45% of conventional adenocarcinoma, 14.81% in pure BACs, and 22.58% in adenocarcinma mixed subtype.
  • EGFR gene amplification might be associated with the development of adenocarcinoma of the lung.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719175.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


76. Minamiya Y, Saito H, Takahashi N, Ito M, Imai K, Ono T, Motoyama S, Ogawa J: Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer; 2010 Jun;68(3):466-71
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung.
  • The relation between CXCR4 expression and the clinicopathological characteristics of lung cancer and patient prognosis is not well understood and remains controversial.
  • We therefore investigated the relationship between CXCR4 expression and prognosis in patients with adenocarcinoma of the lung.
  • METHODS: We used semi-quantitative real time reverse transcription polymerase chain reaction to assess expression of CXCR4 mRNA in tumor samples from 79 patients with adenocarcinoma of the lung.
  • CONCLUSION: Higher levels of CXCR4 expression by tumor cells are an independent predictor of a better prognosis in patients with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers / metabolism. Lung Neoplasms / diagnosis. Receptors, CXCR4 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19716197.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4
  •  go-up   go-down


77. Ohta S, Hirose M, Ishibashi H, Muro H: [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?]. Kyobu Geka; 2007 Jul;60(7):519-22; discussion 522-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is adjuvant chemotherapy necessary for the peripherally located stage I adenocarcinoma of the lung?].
  • OBJECTIVE: This study was done for the purpose of picking out the cases of poor prognosis from the peripherally located stage I adenocarcinoma of the lung.
  • METHODS: Between January 1989 and December 2004, 235 patients with peripherally located stage I adenocarcinoma of the lung were resected curatively in our hospital.
  • CONCLUSIONS: Ductal invasion is significant prognostic factor in stage I adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642210.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Yu J, Pan T, Li J, Wei X, Chen T, Hu M, Song D, Liu L, Chen P: [Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2006;9(4):325-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung].
  • The aim of this study is to investigate the levels of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung, and to clearly understand their roles in growth, invasion and metastasis of squamous cell carcinoma and adenocarcinoma.
  • METHODS: OPN, CD44v6 and MMP-2 were detected in 69 patients with squamous cell carcinoma and adenocarcinoma by immunohistochemical method.
  • RESULTS: The expression rate of OPN, CD44v6 and MMP-2 was significantly related to histological classification, TNM stages and lymph node metastasis (P < 0.05), but not to cell differentiation (P > 0.05).
  • CONCLUSIONS: OPN, CD44v6 and MMP-2 expression is related to the histology, TNM stages and lymph node metastasis of lung cancer.
  • They might be used as clinical indicators to predict the progress and metastatic potential for squamous cell carcinoma and adenocarcinoma of the lung.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176447.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


79. Shenglin M, Yaping X, Xinmin Y, Yang Y: Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients.
  • : e19030 Background: The detection of brain metastasis(BM) is becoming increasingly common in patients with non-small cell lung cancer (NSCLC).
  • Variables analyzed included the recursive partitioning analysis (RPA) grouping, weight loss, LDH in blood serum, sex, age, time of brain metastasis (synchronous vs. metachronous), number of brain metastases, maximum diameter of largest brain lesion, Karnofsky performance status, histologic type (adenocarcinoma vs. other types of NSCLC), TNM stage (without consideration of brain involvement), and the treatment modality used for both the primary NSCLC tumor and brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, Aokage K, Yanagi S, Nagai K, Nishiwaki Y, Ochiai A: Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol; 2010 Sep;5(9):1361-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness.
  • The purpose of this study was to evaluate the clinicopathologic significance of tumor budding in adenocarcinomas of the lung.
  • METHODS: We investigated the relationship between tumor budding and clinicopathologic parameters of adenocarcinomas of the lung and the prognostic significance of tumor budding by reviewing the cases of 201 consecutive patients who had undergone complete resection of adenocarcinoma of the lung measuring 30 mm or less in diameter.
  • RESULTS: Tumor budding was observed in 78 (43.1%) of the 181 cases with invasive adenocarcinoma.
  • Compared with cancer cells forming nests, BCs displayed reduced expression of cellular adhesion molecule, E-cadherin, and beta-catenin (p < 0.05 and p < 0.05, respectively) and increased expression of laminin5-gamma2 (p < 0.05).
  • Multivariate analysis revealed that tumor budding was significant independent prognostic factor of the small-sized adenocarcinoma of the lung.
  • CONCLUSIONS: Our data showed that tumor budding in adenocarcinoma of the lung is a distinct morphologic feature that has biologic and prognostic significance.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Cadherins / metabolism. Cell Adhesion Molecules / metabolism. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Tissue Array Analysis. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631633.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / beta Catenin; 0 / kalinin
  •  go-up   go-down


81. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • : 11001 Background: Cancer cells possess traits reminiscent of those ascribed to normal stem cells.
  • It is unclear whether these phenotypic similarities between normal/embryonic stem cells and mature tumor cells, specific to lung cancer, are a result of underlying biologic processes, such as specific molecular pathways and regulatory networks.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • GSEA identified gene sets significantly represented in the ES signature: signature of neoplastic transformation, signature of undifferentiated cancer, BRCA pathway, and fibroblast serum response pathway, all associated with cancer invasiveness.
  • Adenocarcinomas with ES demonstrated increased activation of RAS (p = 0.0002), MYC (p = 0.0057), wound healing (angiogenesis) (p < 0.0001), chromosomal instability (p < 0.0001), and invasiveness (p < 0.0001) gene signatures.
  • Adenocarcinomas (N= 634) with ES had a decreased survival (p<0.04).
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).
  • CONCLUSIONS: Lung adenocarcinomas that share a common gene expression pattern with normal stem cells were associated with decreased survival and increased likelihood of resistance to cisplatin, indicating the aggressiveness of lung tumors with a stem cell phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis and treatment is unclear.
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Contralateral low grade AS in one woman, and lung adenocarcinoma in the man, had been diagnosed 2 years later.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Jian Z, Tomizawa Y, Yanagitani N, Iijima H, Sano T, Nakajima T: Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes. Pathol Int; 2005 Oct;55(10):619-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes.
  • To clarify the clinicopathological nature of papillary adenocarcinoma (PA) of the lung, 20 cases of PA were collected consecutively from resected adenocarcinoma of the lung, studied immunohistochemically and, using molecular techniques, compared with bronchioloalveolar carcinoma (BAC).
  • Morphologically, PA was divided into two subtypes according to the presence of residual alveolar structures, detected by elastica van Gieson stain.
  • One of these subtypes was closely related to the morphology of BAC and might be diagnosed as adenocarcinoma with mixed subtypes.
  • The other PA subtype was composed of tall columnar cells and grew compressively, which was similar to type F adenocarcinoma previously reported by Noguchi et al.
  • Immunohistochemical studies using lung tissue-specific antigens, progression markers and tumor suppressor products found that PA seemed a more advanced adenocarcinoma than BAC, but no differences were observed among PA subtypes.
  • These findings suggest that PA is a more advanced adenocarcinoma subtype than BAC.
  • Further investigations are needed to clarify true PA as clinicopathologically and biologically independent from other histological subtypes of adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185291.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


84. González-Aragoneses F, Moreno-Mata N, Cebollero-Presmanes M, García-Yuste M, Cañizares-Carretero MA, Molins-López-Rodó L, Quevedo-Losada S, Torres-Lanzas J, Alvarez-Fernández E, Spanish Multicenter Study of Neuroendocrine Tumours of the Lung of the Spanish Society of Pneumonology, ThoracicSurgery (EMETNE-SEPAR): Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung. Cancer; 2007 Oct 15;110(8):1776-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung.
  • BACKGROUND: The prognostic significance of the presence of a neuroendocrine marker (synaptophysin, SY) was analyzed in stage I of squamous carcinoma and adenocarcinoma of the lung.
  • METHODS: A multicentric retrospective study was conducted with immunohistochemical staining in a single center of 318 patients resected for squamous carcinoma or adenocarcinoma in pathologic stage I.
  • RESULTS: In all, 162 cases of squamous carcinoma and 156 cases of adenocarcinoma were identified, which included 105 patients in stage IA (50 patients with squamous carcinoma and 55 patients with adenocarcinoma) and 213 in stage IB (112 with squamous carcinoma and 101 with adenocarcinoma).
  • CONCLUSIONS: Stage I of squamous carcinoma and adenocarcinoma of the lung with SY+ has a poor prognosis, with a higher frequency of recurrence and lower survival rates.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Recurrence, Local / metabolism. Synaptophysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724707.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin
  •  go-up   go-down


85. Okutani D, Yamane M, Toyooka S, Oto T, Aoe M, Sano Y, Date H: Dry small pleural dissemination of adenocarcinoma of the lung preoperatively detected by PET/CT: a report of two cases. Acta Med Okayama; 2008 Feb;62(1):55-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dry small pleural dissemination of adenocarcinoma of the lung preoperatively detected by PET/CT: a report of two cases.
  • Dry pleural dissemination in non-small cell lung cancer, defined as solid pleural metastasis of lung cancer without pleural effusion, is a condition occurring in T4 lung cancer.
  • Positron emission tomography (PET) has been reported to be useful for the diagnosis and staging of lung cancer.
  • We encountered two cases of dry small pleural dissemination of adenocarcinoma of the lung preoperatively detected by PET/CT.
  • A 75-year-old man and a 66-year-old man underwent CT scan, which demonstrated solitary tumor in the lung, an enlarged mediastinal lymph node, and a small pleural nodule less than 10 mm in size, all of which were positive findings on the fluorine 18 fluorodeoxyglucose (FDG) PET portion of an integrated PET/CT.
  • Both patients underwent thoracoscopic biopsy of the dry pleural nodule revealing dissemination of adenocarcinoma of the lung (T4).
  • Whereas histological thoracoscopic diagnosis remains mandatory before planning treatment, our cases may suggest that PET/CT will be useful as a screening modality for dry pleural dissemination of lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / secondary. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Pleural Neoplasms / diagnostic imaging. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323864.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Suzaki N, Hiraki A, Takigawa N, Ueoka H, Tanimoto Y, Kozuki T, Tabata M, Kanehiro A, Kiura K, Tanimoto M: Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama; 2006 Oct;60(5):295-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung.
  • A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel.
  • Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer.
  • This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / adverse effects. Lung Diseases, Interstitial / chemically induced. Lung Neoplasms / drug therapy. Paclitaxel / adverse effects

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072376.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


87. Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H: Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med; 2010 Apr;51(4):535-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implication of dual-phase PET in adenocarcinoma of the lung.
  • The purpose of this study was to determine whether dual-phase (18)F-FDG PET could be a prognostic factor for adenocarcinoma of the lung.
  • METHODS: One hundred patients with histologically proven adenocarcinoma of the lung were included in this retrospective analysis.
  • The percentage change in the maximal standardized uptake values (SUVmax) of the cancer between the early and the delayed images was calculated.
  • RESULTS: Statistical analysis showed that SUVmax change over time between the early and the delayed PET was a strong independent predictor of outcome for lung adenocarcinoma.
  • Our findings suggest that the percentage SUVmax change over time is a strong prognostic factor in patients with lung adenocarcinoma and can be complementary to the other well-known factors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / radionuclide imaging. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237037.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER, Lock V, Squires M, Fazal L, Judson I: A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure of solid tumour cell lines to AT9283 in vitro induces an "aurora inhibitory" phenotype.
  • Cell survival decreases with increased duration of exposure.
  • An additional 4 patients received at least six cycles of therapy (squamous cell carcinoma of the lung, adenocarcinoma of the esophagus and colorectal carcinoma [2]) with a best response of stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Zheng H, Wang J, Meng Q, Liu Z, Li B, Zhu Y: [Target therapy of gefitinib in advanced adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):229-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Target therapy of gefitinib in advanced adenocarcinoma of the lung].
  • BACKGROUND: Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which is used to treat advanced non-small cell lung cancer, especially adenocarcinoma.
  • The aim of this study is to evaluate the efficacy, side effects and prognostic factors of gefitinib in adenocarcinoma of the lung.
  • METHODS: A total of 26 patients with advanced adenocarcinoma of the lung were enrolled in the study.
  • It can significantly improve quality of life of patients with adenocarcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118653.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Van Dyke AL, Cote ML, Prysak GM, Claeys GB, Wenzlaff AS, Murphy VC, Lonardo F, Schwartz AG: COX-2/EGFR expression and survival among women with adenocarcinoma of the lung. Carcinogenesis; 2008 Sep;29(9):1781-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2/EGFR expression and survival among women with adenocarcinoma of the lung.
  • Previous studies suggest that cyclooxygenase-2 (COX-2) expression may predict survival among patients with non-small cell lung cancer.
  • The extent to which their independent or combined expression is associated with prognosis in women with adenocarcinoma of the lung is unknown.
  • In the present study, we examined relationships between COX-2 expression (n = 238), EGFR expression (n = 158) and dual COX-2/EGFR expression (n = 157) and survival among women with adenocarcinoma of the lung.
  • Overall survival was estimated by constructing Cox proportional hazards models adjusting for other significant variables and stratifying by stage at diagnosis and race.
  • African-Americans with COX-2-positive tumors had a statistically non-significant higher risk of death than African-Americans with COX-2-negative tumors (HR 5.58, 95% CI 0.64-48.37).
  • In conclusion, COX-2 and EGFR expression, but not combined COX-2+/EGFR+ expression, independently predict survival of women with adenocarcinoma of the lung.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):241-9 [9516978.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3761-4 [9731479.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4245-9 [9766645.001]
  • [Cites] Am J Public Health. 1998 Nov;88(11):1681-4 [9807536.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):515-22 [9815714.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4575-83 [15542809.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1265-73 [15712203.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):545-55 [15704107.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Arch Pathol Lab Med. 2005 Sep;129(9):1113-7 [16119982.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):25-31 [16434582.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):928-34 [16521222.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8 [16740761.001]
  • [Cites] Clin Lung Cancer. 2006 May;7(6):389-94 [16800964.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):139-45 [16786043.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1198-204 [16996907.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):387-98 [17011067.001]
  • [Cites] Cancer Invest. 2002;20(5-6):651-6 [12197220.001]
  • [Cites] Eur Respir J. 2002 Oct;20(4):975-81 [12412692.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):171-7 [12633561.001]
  • [Cites] Oncol Res. 2003;13(5):289-98 [12688680.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):78-86 [14750244.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] Acta Oncol. 2004;43(1):80-6 [15068324.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):208-12 [15187994.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1632-8 [15378500.001]
  • [Cites] J Clin Immunol. 1983 Oct;3(4):295-315 [6140268.001]
  • [Cites] Br J Cancer. 1987 May;55(5):513-6 [3038157.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7077-80 [2208175.001]
  • [Cites] Am J Public Health. 1991 Nov;81(11):1483-6 [1951809.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2379-85 [7683573.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):162-5 [8391303.001]
  • [Cites] J Natl Cancer Inst. 1996 Feb 21;88(3-4):183-92 [8632492.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):447-52 [17082511.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):752-60 [17317677.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):299-305 [17409801.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2248-55 [17538169.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3266-73 [17664473.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 19;99(18):1384-94 [17848670.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Nov;37(5):578-88 [17600311.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2775-84 [17948911.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5785-92 [18089876.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):374-9 [18379355.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1001-5 [10353732.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Lung Cancer. 2000 Nov;30(2):73-81 [11086200.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):11-31 [11350724.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1850-5 [11448895.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):284-90 [11854390.001]
  • (PMID = 18453539.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC35145; United States / NCI NIH HHS / CA / P30CA22453; United States / NCI NIH HHS / CA / R01-CA87895
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2527644
  •  go-up   go-down


91. Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M: A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg; 2008 Mar;135(3):627-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A simple two-gene prognostic model for adenocarcinoma of the lung.
  • OBJECTIVE: We hypothesized that clinical outcome of resected early-stage adenocarcinoma of the lung can be predicted by the expression of a few critically important genes as measured by quantitative real-time reverse-transcriptase polymerase chain reaction in formalin-fixed paraffin-embedded primary tumors.
  • METHODS: Twenty-two prognostic genes for the metastatic phenotype were identified through complementary DNA microarray analysis of 4 cancer cell lines and bioinformatics analysis.
  • Expression levels of a subset of these genes (n = 13) were measured by real-time time reverse-transcriptase polymerase chain reaction in formalin-fixed paraffin-embedded primary adenocarcinoma from patients whose disease recurred within 2 years (n = 9) and in patients who did not have a recurrence (n = 11).
  • CONCLUSIONS: This preliminary study provides evidence that the CK19/EpCAM2 and/or CK19/P-cadherin ratio(s) may be a simple and accurate prognostic indicator of clinical outcome in early-stage adenocarcinoma of the lung.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] OMICS. 2006 Winter;10(4):429-43 [17233555.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3005-8 [12036904.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Chest. 2002 Sep;122(3):1037-57 [12226051.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):905-10 [14504202.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 [14573703.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):811-9 [14990636.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1090-8 [15448693.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6897-904 [15501967.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43 [10096969.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6146-54 [15579771.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3092-9 [15833838.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3697-704 [15897566.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3057-63 [16707602.001]
  • [Cites] Respirology. 2007 Jan;12(1):22-8 [17207021.001]
  • (PMID = 18329483.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097875-01; United States / NCI NIH HHS / CA / R21 CA097875-01
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALM2 protein, human; 0 / Cadherins; 0 / Calmodulin; 0 / Keratin-19
  • [Other-IDs] NLM/ NIHMS146466; NLM/ PMC2774741
  •  go-up   go-down


92. Di Maio M, Camps C, Smit EF, Schuette W, Georgoulias V, Takeda K, Quoix E, Wachters FM, Gebbia V, Gridelli C: Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials. J Clin Oncol; 2009 May 20;27(15_suppl):8082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients enrolled in clinical trials of second-line chemotherapy for advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 11 randomized trials.
  • Of the other 9 trials (1239 pts), 1197 pts (97%) had complete information: 78%/22% males / females, 83%/17% younger / older than 70, 28%/59%/13% Performance Status (PS) 0 / 1 / 2, 18%/82% stage IIIB / IV, 32%/47%/21% squamous / adenocarcinoma / other histology.
  • At multivariate analysis, prognosis was significantly influenced by gender (worse in males vs females, Hazard Ratio [HR] 1.23 [95%CI 1.04-1.45], p=0.01), by PS (worse in PS1 vs PS0, HR 1.36 [1.16-1.59], p=0.0001 and in PS2 vs PS0, HR 3.01 [2.41-3.76], p<0.00001), by tumor histology (better in adenocarcinoma vs squamous, HR 0.85 [0.73-0.99], p=0.04 and worse in other histology vs squamous, HR 1.27 [1.05-1.52], p=0.01), by stage (worse in stage IV vs IIIB, HR 1.28 [1.07-1.53], p=0.007), by type of previous treatment (worse for pts pretreated with platin vs pts not pretreated with platin, HR 1.49 [1.14-1.93], p=0.003), and worse for pts not obtaining OR vs pts obtaining OR during 1<sup>st</sup> line (HR 1.25 [1.10-1.44], p=0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962659.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Iguchi Y, Mano K, Goto Y, Nakano T, Nomura F, Shimokata T, Iwamizu-Watanabe S, Hashizume Y: Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation. Neuroradiology; 2007 Jan;49(1):35-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miliary brain metastases from adenocarcinoma of the lung: MR imaging findings with clinical and post-mortem histopathologic correlation.
  • METHODS: We report a 66-year-old man with miliary brain metastases from adenocarcinoma of the lung, describing MRI and neuropathologic findings in the context of previously reported cases.
  • CONCLUSION: We should consider this pattern of brain dissemination when a cancer is associated with unexplained disturbance of consciousness.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / secondary. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1988;30(3):265-8 [3405417.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1551-5 [8608542.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1951 Feb;65(2):161-73 [14798993.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):564-6 [9046318.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):553-4 [3111217.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 May-Jun;14 (3):540-2 [8517338.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23 ):4340-1 [11731517.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):110-1 [8429312.001]
  • [Cites] Neuropathology. 2005 Jun;25(2):153-8 [15875909.001]
  • [Cites] Neuroradiology. 1997 Jun;39(6):437-40 [9225326.001]
  • [Cites] Neurology. 1987 Nov;37(11):1817-8 [3670620.001]
  • [Cites] Neuroradiology. 1989;31(2):200 [2747904.001]
  • (PMID = 17103154.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Noguchi M, Minami Y, Iijima T, Matsuno Y: Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria. Pathol Int; 2005 Jan;55(1):8-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteria.
  • Using 32 small adenocarcinomas of the lung including bronchioloalveolar carcinoma (BAC), the reproducibility of diagnosis by the modified diagnostic criteria for small adenocarcinoma (Cancer 75; 2844, 1995) and the effectiveness of an educational program for 27 volunteer general pathologists were examined.
  • The average coincidence rate of the diagnosis before and after the program was 42.4% and 56.6%, respectively.
  • In contrast, the average coincidence rate of six lung cancer specialists was 71.4%, and this was significantly higher than that for general pathologists after the program (P < 0.05).
  • When the cases were divided into two groups (in situ adenocarcinoma (BAC and BAC with alveolar collapse) and early invasive adenocarcinoma), the average coincidence rate for the general pathologists after the program increased to 85.3%, which was significantly higher than that before the program (80.3%; P < 0.05).
  • This trial was thought to provide a theoretical background for the histological diagnosis of peripheral type adenocarcinoma of the lung and to justify the existing diagnostic criteria.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Lung Neoplasms / diagnosis. Pathology, Surgical / education
  • [MeSH-minor] Diagnosis, Differential. Humans. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660697.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


95. Cho S, Sung SW, Jheon S, Chung JH: Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis. Lung; 2008 Nov-Dec;186(6):411-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.
  • STUDY OBJECTIVES: Stage I adenocarcinoma of the lung is the most common type of lung cancer.
  • A better understanding of the histopathology and molecular biology of lung cancer might improve the capability to predict the outcome for any individual patient.
  • The purpose of this study was to evaluate several histopathologic and molecular markers in order to assess their prognostic value in stage I adenocarcinoma.
  • CONCLUSIONS: In resected stage I adenocarcinoma, necrosis, lymphatic vessel invasion, E-cadherin, and p53 have been identified as independent predictors of disease-free survival.
  • [MeSH-major] Adenocarcinoma / pathology. Cadherins / analysis. Ki-67 Antigen / analysis. Lung Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1996 Jan;178(1):53-8 [8778317.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Mar;115(3):652-8; discussion 658-9 [9535454.001]
  • [Cites] J Surg Oncol. 1987 Jul;35(3):147-56 [3037195.001]
  • [Cites] Ann Thorac Surg. 1995 Aug;60(2):466-72 [7646126.001]
  • [Cites] Thorax. 2001 Jul;56(7):561-6 [11413356.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4789-96 [11156236.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4828-31 [1324796.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] J Thorac Oncol. 2007 Sep;2(9):808-12 [17805057.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43 [10096969.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4055-63 [11051256.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1265-79 [7738631.001]
  • [Cites] Ann Thorac Surg. 1990 Feb;49(2):242-6; discussion 246-7 [2154958.001]
  • [Cites] Eur Respir J. 2001 Oct;18(4):705-19 [11716177.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):949-54; discussion 954-5 [11269479.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Jul;106(1):80-9 [8391612.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2464-70 [8625072.001]
  • [Cites] Cancer. 1988 May 15;61(10):2083-8 [3359406.001]
  • [Cites] Chest. 2003 Jun;123(6):1858-67 [12796161.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1470-6 [8633961.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4575-83 [15542809.001]
  • [Cites] Ann Thorac Surg. 1984 Oct;38(4):331-8 [6091575.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Oct;108(4):684-6 [7934103.001]
  • (PMID = 18836777.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


96. Longo M, Levra MG, Capelletto E, Billè A, Ardissone F, Familiari U, Novello S: Fetal adenocarcinoma of the lung in a 25-year-old woman. J Thorac Oncol; 2008 Apr;3(4):441-3
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal adenocarcinoma of the lung in a 25-year-old woman.
  • A pathologic diagnosis of well-differentiated fetal adenocarcinoma of the lung was made and staged as T2N0.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Pulmonary Blastoma / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Female. Humans. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379367.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Chiu WK, Lin YC, Wang LT, Chen JH, Yu JC, Hsieh CB: Jejunojejunal intussusception secondary to metastasis from adenocarcinoma of the lung--a case report. Acta Chir Belg; 2009 Jul-Aug;109(4):519-22
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jejunojejunal intussusception secondary to metastasis from adenocarcinoma of the lung--a case report.
  • Small intestine metastasis from primary lung cancer is uncommon and jejunojejunal intussusception secondary to metastatic lung cancer is extremely rare.
  • Chest roentgenogram showed a mass lesion in the right upper lung zone.
  • Biopsy of the lung mass lesion confirmed adenocarcinoma of the lung.
  • Histological examination of the specimen revealed metastatic adenocarcinoma of lung origin.
  • [MeSH-major] Adenocarcinoma / secondary. Intussusception / etiology. Jejunal Diseases / etiology. Jejunal Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803270.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


98. Novello S, Abrey LE, Grossi F, Camps C, Mazieres J, Selaru P, Patyna S, Torigoe Y, Chao R, Scagliotti G: Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial.
  • : 8077 Background: Sunitinib (SU), an oral, multitargeted inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R, and RET has promising single-agent antitumor activity in refractory non-small cell lung cancer (NSCLC) (Socinski JCO 2008).
  • Safety was assessed by monitoring adverse events (AEs) and health-related quality of life was assessed using FACT/NCCN Lung Symptom Index (FLSI) and Brain Symptom Index (FBrSI).
  • RESULTS: To date, 47 pts, including 28 with adenocarcinoma and 10 with squamous cell carcinoma, received SU for a median of 2 cycles (range: 1, 9).
  • In total, 25 pts (53%) experienced non-neurologic grade (G) 3/4 AEs; the most frequent were fatigue/asthenia and dyspnea.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Shinmura K, Suzuki M, Yamada H, Tao H, Goto M, Kamo T, Nagura K, Kageyama S, Kato M, Ogawa S, Maekawa M, Takamochi K, Suzuki K, Nakamura T, Sugimura H: Characterization of adenocarcinoma of the lung in a familial adenomatous polyposis patient. Pathol Int; 2008 Nov;58(11):706-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of adenocarcinoma of the lung in a familial adenomatous polyposis patient.
  • The incidence of several extracolonic tumors, such as duodenal carcinoma, is higher in familial adenomatous polyposis (FAP) patients than in the general population, but there is little information about lung carcinoma in FAP.
  • A 43-year-old woman presented with a lung tumor 17 years after total colectomy for FAP.
  • Pathohistological analysis of the lung tumor demonstrated mixed adenocarcinoma consisting of a papillary adenocarcinoma component and a bronchioloalveolar carcinoma component.
  • The other APC allele in the lung carcinoma was not inactivated by somatic mutations, promoter methylation, or chromosomal deletion.
  • The present results suggest that the chromosomal copy number alterations detected on SNP microarray were involved in the carcinogenesis of the adenocarcinoma of the lung in the present FAP patient.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Adenomatous Polyposis Coli / pathology. Lung Neoplasms / pathology


100. Lu P, Zhang D, Gao Y, Hu C: [Expression and significance of TSG101, P21 and P300/CBP in squamous cell carcinoma and adenocarcinoma of the lung]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):197-202
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of TSG101, P21 and P300/CBP in squamous cell carcinoma and adenocarcinoma of the lung].
  • This study is designed to investigate the relationship between sex, age, tumor size, histological type, differentiation, clinical stage and lymphnode metastasis with the expression of TSG101 in human squamous cell carcinoma and adenocarcinoma of the lung, and to analyze whether there is relativity between TSG101, P21 and P300/CBP.
  • METHODS: Immunohistochemical method (SP method) was adopted to detect the expression of TSG101, P21 and P300/CBP proteins in cancer tissues and neighboring noncancerous tissues of 79 cases of human squamous cell carcinoma and adenocarcinoma of the lung.
  • Western blot method was adopted to detect the expression of TSG101 protein in 26 tumor tissues and normal tissues adjacent to cancer.
  • CONCLUSIONS: The expression of TSG101, P21 and P300/CBP protein might be associated with lung cancer differentiation and metastasis, the expression of them is positively correlated with each other, hence they can be used as valuable biomarkers to evaluate lung cancer metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118645.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement